Israeli researchers say spirulina algae could reduce COVID mortality rate
if(window.location.pathname.indexOf(“656089”) != -1){console.log(“hedva connatix”);document.getElementsByClassName(“divConnatix”)[0].style.display =”none”;}
“In this study, it was exciting to discover such activity in algae that was grown under controlled conditions, using sustainable aquaculture methods,” said MATIS’s Dr. Sophie Jensen. “Although active ingredients have not yet been identified with absolute certainty, the extract opens a space for clinical trials that offer a variety of anti-inflammatory treatments, for COVID-19 and beyond.”Tzachor said that the team now hopes to run human clinical trials.“If clinical trials confirm the efficacy of our suggested therapy at the rates reported, the substance can become available to the general population,” he said.“We hope this research would urge the communities of regulators and investors and pharma companies to invest more resources and give more attention to natural-based therapies. The potential is unbelievable.”
Comments are closed.